17 studies found for:    "Noonan syndrome 5"
Show Display Options
Rank Status Study
1 Completed Assessing Single and Multiple Doses of HCV NS5A Inhibitor IDX719 in Healthy and HCV-Infected Subjects
Condition: Hepatitis C, Chronic
Intervention: Drug: IDX719 or matching placebo (oral suspension)
2 Completed Ph IIA Study (SOC +/- NS5B)
Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325;   Drug: Placebo;   Drug: Peg-interferon alfa-2a;   Drug: Ribavirin
3 Recruiting TD-6450 SAD and MAD in Healthy Subjects
Condition: Hepatitis C
Interventions: Drug: TD-6450;   Drug: Placebo
4 Recruiting TD-6450 MAD Study in HCV Infected Subjects
Conditions: Hepatitis C;   HCV
Interventions: Drug: TD-6450;   Drug: Placebo
5 Active, not recruiting Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: PPI-668;   Drug: BI 207127 Dose 1;   Drug: BI 207127 Dose 2;   Drug: Faldaprevir;   Drug: Ribavirin;   Drug: BI 207127 Placebo
6 Completed A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2878175;   Drug: Placebo
7 Active, not recruiting Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2878175;   Drug: Placebo
8 Completed A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: HCV Infection
Interventions: Drug: GS-5885;   Drug: Placebo
9 Completed A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
Condition: Chronic Genotype 1 Hepatitis C Virus Infection
Interventions: Drug: PPI-461;   Drug: Placebo
10 Completed A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-668;   Drug: Placebo
11 Active, not recruiting Dose Ranging of GSK2336805 in Combination Therapy
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805 40 mg;   Drug: GSK2336805 60 mg;   Drug: Pegylated interferon alpha-2a;   Drug: Ribavirin;   Drug: Telaprevir
12 Completed Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects
Condition: Hepatitis C Virus
Interventions: Drug: sovaprevir;   Drug: ACH-3102;   Drug: Ribavirin;   Drug: Placebo
13 Completed Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: GSK2336805 Matching Placebo
14 Recruiting A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-383;   Drug: Placebo
15 Terminated GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
Condition: Chronic Hepatitis C
Interventions: Drug: GS-5885;   Drug: GS-9451;   Drug: RBV;   Drug: PEG
16 Recruiting A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
Condition: Chronic Hepatitis C Infection
Interventions: Drug: JNJ-47910382 30 mg;   Drug: JNJ-47910382 90 mg;   Drug: JNJ-47910382 200 mg;   Drug: Placebo
17 Terminated Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Placebo;   Drug: JNJ-47910382

Indicates status has not been verified in more than two years